Mahato Deependra, De Biase Gaetano, Ruiz-Garcia Henry J, Grover Surbhi, Rosenfeld Steven, Quiñones-Hinojosa Alfredo, Trifiletti Daniel M
Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL, United States.
Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL, United States; Department of Neurological Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
J Clin Neurosci. 2018 Dec;58:34-41. doi: 10.1016/j.jocn.2018.10.078. Epub 2018 Oct 23.
Low grade gliomas present unique and challenging scenarios. We aimed to identify if facility type and/or facility volume impact overall survival (OS) following diagnosis of WHO grade II gliomas. We also sought to compare early post-surgical outcomes based on these factors.
The National Cancer Database was queried for patients with WHO grade II gliomas diagnosed from 2004 to 2013 with known survival. Patients were grouped based on facility type and facility volume. Multivariable analyses were performed to investigate factors associated with OS following diagnosis, and Chi-square tests were used to compare early post-surgical outcomes.
6428 patients met inclusion criteria. Factors associated with improved OS on multivariable analysis included younger patient age, female gender, race, non-use of radiotherapy (each p < 0.001). Also, on multivariable analysis, OS was improved among patients treated at Academic/Research programs compared to those treated at Non-Academic/Research programs (HR 0.898, p = 0.014), but facility volume did not impact OS (p = 0.760). Thirty-day mortality did not differ by facility type (p = 0.265), but 90-day morality as well as 30-day readmission rates were more favorable in Academic/Research programs (p = 0.008 and <0.001, respectively).
This study suggests that patients treated in Academic/Research programs have increased survival and generally more favorable early-postsurgical outcomes. The extent to which differences in patient populations, socioeconomic factors, and/or provider expertise play into this cause will be areas of future research.
低级别胶质瘤呈现出独特且具有挑战性的情况。我们旨在确定医疗机构类型和/或机构规模是否会影响世界卫生组织(WHO)二级胶质瘤诊断后的总生存期(OS)。我们还试图基于这些因素比较术后早期结果。
查询国家癌症数据库中2004年至2013年诊断为WHO二级胶质瘤且已知生存情况的患者。患者根据医疗机构类型和机构规模进行分组。进行多变量分析以研究诊断后与总生存期相关的因素,并使用卡方检验比较术后早期结果。
6428名患者符合纳入标准。多变量分析中与总生存期改善相关的因素包括患者年龄较小、女性性别、种族、未接受放疗(各p<0.001)。此外,多变量分析显示,与在非学术/研究项目接受治疗的患者相比,在学术/研究项目接受治疗的患者总生存期有所改善(风险比0.898,p = 0.014),但机构规模并未影响总生存期(p = 0.760)。30天死亡率在不同医疗机构类型之间无差异(p = 0.265),但学术/研究项目的90天死亡率以及30天再入院率更有利(分别为p = 0.008和<0.001)。
本研究表明,在学术/研究项目接受治疗的患者生存期延长,且术后早期结果总体上更有利。患者群体差异、社会经济因素和/或医疗服务提供者专业知识在其中所起作用的程度将是未来研究的领域。